KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Alterome Therapeutics, Inc.
Astellas Pharma Inc
Tizona Therapeutics, Inc
Bristol-Myers Squibb
Mirati Therapeutics Inc.
BioAtla, Inc.
Pfizer
Sanofi
Celgene
GlaxoSmithKline
Biond Biologics
Eisai Inc.
NKGen Biotech, Inc.
Eli Lilly and Company
Bayer
Eli Lilly and Company
Novartis
Merck Sharp & Dohme LLC
Eli Lilly and Company
Eli Lilly and Company
AbbVie
Merck KGaA, Darmstadt, Germany
Hoffmann-La Roche
Eli Lilly and Company
Regeneron Pharmaceuticals
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Eli Lilly and Company
Eli Lilly and Company
Harrison Clinical Research